BioVaxys enters into a major bioproduction agreement with Wuxi Biologics (Hong Kong) Ltd.


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ BioVaxys enters into a major bioproduction agreement with Wuxi Biologics (Hong Kong) Ltd.

BioVaxys Technology Corp., the world leader in haptenized protein vaccines for antiviral and cancer applications, announced that it has entered into a major agreement of bioproduction with WuXi Biologics Limited ("WuXi"), world-leading contract development and research organization ("CDMO") and a business unit of Shanghai-based Wuxi AppTec, to produce SARS-CoV-2 s-required proteins by BioVaxys for BVX-0320, and its COVID-19 vaccine candidate, and for its Covid-T immunodiagnostic program.

Within the terms of the agreement on March 11, 2021, WuXi will synthesize comprehensive results of fully characterized SARS-CoV-2 Good Laboratory Practice (GLP) grade proteins for BioVaxys preclinical safety study of its COVID-diagnosis, this spring. Recombinant protein s will be constructed and expressed using WuXi Biologics' proprietary vector, with high protein production in a pilot plant bioreactor. By establishing its own protein source, rather than relying on a commercial bulk supplier, BioVaxys will be able to ensure the level of protein purity, consistency, and characterization required by the US Food and Drug Administration ("the FDA"), as well as the economics of generating your own protein supply,

The synthesized GMP-grade protein s is used in BioVaxys' Covid-T immunodiagnostics as well as BVX-0320, the company's SARS-CoV-2 vaccine candidate, which is also being prepared for this clinical study. anus. BioVaxys will submit its pre-IND petition to the FDA for Covid-T early next month.

Ken Kovan, CEO and COO of BioVaxys, stated: "Establishing a bioproduction method for a stable supply of purified and fully characterized protein s from a validated process will allow us to move quickly from having the GLP material to the next toxicity study. Covid-T ™ animal to have a stable source of GMP-grade proteins for clinical trials later this year. Now that we know the genetic sequences, an important benefit of our relationship with WuXi will be our ability to rapidly generate the proteins from emerging SARS-CoV-2 variants for use in a planned multivalent version of BVX-0320 and Covid-T  line extensions. "

James Passin, CEO of BioVaxys, commented: "We are delighted to execute a definitive agreement with WuXi Biologics, a China-based CDMO listed on the Hong Kong Stock Exchange under the symbol 2269, with a market capitalization of 45 billion US dollars. The relationship with WuXi positions BioVaxys to accelerate the regulatory and commercial advance of Covid-T and BVX-0320. "

For greater certainty, BioVaxys will make no express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.

Tags : #Biovaxys #WuxiBiologics #HongKong #CovidTreatment #CDMO #LatestpharmanNews

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026